Meeting
2023 ASCO Annual Meeting
Artificial intelligence (AI) –powered spatial analysis of tumor-infiltrating lymphocytes (TILs) for prediction of prognosis in resectable pancreatic adenocarcinoma (PDAC).
Authors
Yoojoo Lim
Oncology, Lunit, Seoul, South Korea
Yoojoo Lim , Jin Ho Choi , Hyemin Kim , In Woong Han , Sanghoon Song , Jiwon Shin , Heon Song , Seonwook Park , Sergio Pereira , Sang Hyun Shin , Jin Seok Heo , Kwang Hyuck Lee , Kyu Taek Lee , Jong Kyun Lee , Kee-Taek Jang , Chan-Young Ock , Joo Kyung Park
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer - Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4162)
DOI
10.1200/JCO.2023.41.16_suppl.4162
Abstract #
4162
Poster Bd #
483
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.
First Author: Choong-kun Lee
Poster
2022 ASCO Annual Meeting
Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Updated final results of the randomized phase II AIO-NEONAX trial.
First Author: Thomas Jens Ettrich
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.
First Author: Choong-kun Lee
Poster
2020 Gastrointestinal Cancers Symposium
Pancreatic adenosquamous carcinoma: Clinical associations, treatment, and outcomes.
First Author: Mindy L. Hartgers